Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Lung Cancer

Free Subscription Articles published in JAMA Oncol Retrieve available abstracts of 101 articles: HTML format

Single Articles

September 2023
1. ALDEA M, Marinello A, Guyon D, Gazzah A, et al
   Prevalence of Thromboembolic Events in Patients With Non-Small Cell Lung Cancer and RET Fusions.
   JAMA Oncol. 2023 Sep 14. doi: 10.1001/jamaoncol.2023.3625.
   PubMed    
   
   
   
2. TACHIHARA M, Tsujino K, Ishihara T, Hayashi H, et al
   Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Phase 2 Nonrandomized Controlled Trial.
   JAMA Oncol. 2023 Sep 7. doi: 10.1001/jamaoncol.2023.3309.
   PubMed     Abstract available
   
   
   
3. GRECO L
   Patients With Brain Metastases Deserve Better-A Hard-Won Perspective.
   JAMA Oncol. 2023;9:1197-1198.
   PubMed    
   
   
   
4. SPAAS M, Sundahl N, Kruse V, Rottey S, et al
   Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors: The CHEERS Phase 2 Randomized Clinical Trial.
   JAMA Oncol. 2023;9:1205-1213.
   PubMed     Abstract available
   
   
   August 2023
5. 
   Coding Errors in Study of Eligibility for Lung Cancer Screening.
   JAMA Oncol. 2023 Aug 31. doi: 10.1001/jamaoncol.2023.3792.
   PubMed    
   
   
   
6. POTTER AL, Yang CJ, Palmer JR
   Coding Error in Study Evaluating Eligibility of US Black Women Under USPSTF Lung Cancer Screening Guidelines.
   JAMA Oncol. 2023 Aug 31. doi: 10.1001/jamaoncol.2023.3505.
   PubMed    
   
   
   
7. LEI J, Zhao J, Gong L, Ni Y, et al
   Neoadjuvant Camrelizumab Plus Platinum-Based Chemotherapy vs Chemotherapy Alone for Chinese Patients With Resectable Stage IIIA or IIIB (T3N2) Non-Small Cell Lung Cancer: The TD-FOREKNOW Randomized Clinical Trial.
   JAMA Oncol. 2023 Aug 3. doi: 10.1001/jamaoncol.2023.2751.
   PubMed     Abstract available
   
   
   
8. RICHTERS A, Yildirim H, Booth CM, Vera Badillo FE, et al
   Changes to Primary End Points in Randomized Clinical Trials on Immune Checkpoint Inhibitors in Urothelial, Renal Cell, and Lung Cancers: A Systematic Review.
   JAMA Oncol. 2023;9:1144-1147.
   PubMed    
   
   
   July 2023
9. ZHANG D, Xi Y, Boffa DJ, Liu Y, et al
   Association of Wildfire Exposure While Recovering From Lung Cancer Surgery With Overall Survival.
   JAMA Oncol. 2023 Jul 27. doi: 10.1001/jamaoncol.2023.2144.
   PubMed     Abstract available
   
   
   June 2023
10. LEE CK, Driscoll E
    Net Clinical Benefit as Measure of Treatment Benefit Among Older Adults With Advanced Incurable Non-Small Cell Lung Cancer.
    JAMA Oncol. 2023 Jun 22. doi: 10.1001/jamaoncol.2023.1535.
    PubMed    
    
    
    
11. VORUGANTI T, Presley CJ, Gross CP
    Net Clinical Benefit as Measure of Treatment Benefit Among Older Adults With Advanced Incurable Non-Small Cell Lung Cancer-Reply.
    JAMA Oncol. 2023 Jun 22. doi: 10.1001/jamaoncol.2023.1538.
    PubMed    
    
    
    
12. SUN L, Bleiberg B, Hwang WT, Marmarelis ME, et al
    Association Between Duration of Immunotherapy and Overall Survival in Advanced Non-Small Cell Lung Cancer.
    JAMA Oncol. 2023 Jun 4:e231891. doi: 10.1001/jamaoncol.2023.1891.
    PubMed     Abstract available
    
    
    
13. MAZIERES J, Paik PK, Garassino MC, Le X, et al
    Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial.
    JAMA Oncol. 2023 Jun 4:e231962. doi: 10.1001/jamaoncol.2023.1962.
    PubMed     Abstract available
    
    
    May 2023
14. PASSARO A, Mok TSK, Attili I, Wu YL, et al
    Adjuvant Treatments for Surgically Resected Non-Small Cell Lung Cancer Harboring EGFR Mutations: A Review.
    JAMA Oncol. 2023 May 11. doi: 10.1001/jamaoncol.2023.0459.
    PubMed     Abstract available
    
    
    April 2023
15. AGGARWAL C, West HJ
    Molecular Marker Testing in Curable Non-Small Cell Lung Cancer-Practice Necessarily Precedes Data.
    JAMA Oncol. 2023 Apr 13. doi: 10.1001/jamaoncol.2023.0251.
    PubMed    
    
    
    March 2023
16. CARROLL CE, Landrum MB, Wright AA, Keating NL, et al
    Adoption of Innovative Therapies Across Oncology Practices-Evidence From Immunotherapy.
    JAMA Oncol. 2023;9:324-333.
    PubMed     Abstract available
    
    
    
17. RICCIUTI B, Awad MM
    Atezolizumab Plus Bevacizumab in TMB-High Non-Small Cell Lung Cancers-The Hunt for Predictive Biomarkers to Optimize Treatment Selection.
    JAMA Oncol. 2023;9:353-354.
    PubMed    
    
    
    February 2023
18. KIM KH, Oh J, Yoon HI
    Sinoatrial Node Radiation Dose and Atrial Fibrillation in Patients With Lung Cancer-Reply.
    JAMA Oncol. 2023 Feb 16. doi: 10.1001/jamaoncol.2022.7878.
    PubMed    
    
    
    
19. WALLS GM, Hanna GG
    Sinoatrial Node Radiation Dose and Atrial Fibrillation in Patients With Lung Cancer.
    JAMA Oncol. 2023 Feb 16. doi: 10.1001/jamaoncol.2022.7875.
    PubMed    
    
    
    
20. SOCINSKI MA, Jotte RM, Cappuzzo F, Nishio M, et al
    Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non-Small Cell Lung Cancer: Pooled Analyses of the Phase 3 IMpower130, IMpower132, and IMpower150 Randomized Clinical Trials.
    JAMA Oncol. 2023 Feb 16. doi: 10.1001/jamaoncol.2022.7711.
    PubMed     Abstract available
    
    
    
21. YEGYA-RAMAN N, Jabbour SK, Feigenberg SJ
    Sinoatrial Node Radiation Dose and Atrial Fibrillation in Patients With Lung Cancer.
    JAMA Oncol. 2023 Feb 16. doi: 10.1001/jamaoncol.2022.7872.
    PubMed    
    
    
    
22. ASLAN V, Yazici O, Ozdemir N
    Increased Tumor Mutation Burden Levels and Sensitivity of Non-Small Cell Lung Cancer to PD-L1 Blockade.
    JAMA Oncol. 2023 Feb 2. doi: 10.1001/jamaoncol.2022.7586.
    PubMed    
    
    
    
23. RICCIUTI B, Wang X, Awad MM
    Increased Tumor Mutation Burden Levels and Sensitivity of Non-Small Cell Lung Cancer to PD-L1 Blockade-Reply.
    JAMA Oncol. 2023 Feb 2. doi: 10.1001/jamaoncol.2022.7589.
    PubMed    
    
    
    
24. ZHANG X, Zhang L
    Increased Tumor Mutation Burden Levels and Sensitivity of Non-Small Cell Lung Cancer to PD-L1 Blockade.
    JAMA Oncol. 2023 Feb 2. doi: 10.1001/jamaoncol.2022.7583.
    PubMed    
    
    
    
25. ZHANG X, Ning C, Zhao H
    Tissue-Based PD-L1 Expression Is the Strongest Predictor of Overall Survival Benefit From ICI in Advanced Gastroesophageal Cancer.
    JAMA Oncol. 2023;9:280.
    PubMed    
    
    
    
26. YOON HH, Shi Q, Ajani JA
    Tissue-Based PD-L1 Expression Is the Strongest Predictor of Overall Survival Benefit From ICI in Advanced Gastroesophageal Cancer-Reply.
    JAMA Oncol. 2023;9:280-281.
    PubMed    
    
    
    
27. YAP DWT, Leone AG, Wong NZH, Zhao JJ, et al
    Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma: A Meta-analysis Including Low PD-L1 Subgroups.
    JAMA Oncol. 2023;9:215-224.
    PubMed     Abstract available
    
    
    
28. BAO Y, Zhang H, Bruera E, Portenoy R, et al
    Medical Marijuana Legalization and Opioid- and Pain-Related Outcomes Among Patients Newly Diagnosed With Cancer Receiving Anticancer Treatment.
    JAMA Oncol. 2023;9:206-214.
    PubMed     Abstract available
    
    
    January 2023
29. VORUGANTI T, Soulos PR, Mamtani R, Presley CJ, et al
    Association Between Age and Survival Trends in Advanced Non-Small Cell Lung Cancer After Adoption of Immunotherapy.
    JAMA Oncol. 2023 Jan 26. doi: 10.1001/jamaoncol.2022.6901.
    PubMed     Abstract available
    
    
    
30. ZHANG B, Zhong H, Han B
    Neoadjuvant Immunotherapy for Patients With Non-Small Cell Lung Cancer-Is a New Era Coming?
    JAMA Oncol. 2023 Jan 26. doi: 10.1001/jamaoncol.2022.6898.
    PubMed    
    
    
    
31. CHARLOT M, Gray J
    First-line Immunotherapy and Clinically Meaningful Survival Benefits for the Oldest Adults With Lung Cancer.
    JAMA Oncol. 2023 Jan 26. doi: 10.1001/jamaoncol.2022.6867.
    PubMed    
    
    
    
32. YAP TA, Bardia A, Dvorkin M, Galsky MD, et al
    Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial.
    JAMA Oncol. 2023;9:40-50.
    PubMed     Abstract available
    
    
    
33. RAKAEE M, Adib E, Ricciuti B, Sholl LM, et al
    Association of Machine Learning-Based Assessment of Tumor-Infiltrating Lymphocytes on Standard Histologic Images With Outcomes of Immunotherapy in Patients With NSCLC.
    JAMA Oncol. 2023;9:51-60.
    PubMed     Abstract available
    
    
    December 2022
34. LEE KWC, Li MSC, Gai W, Lau YM, et al
    Testing for EGFR Variants in Pleural and Pericardial Effusion Cell-free DNA in Patients With Non-Small Cell Lung Cancer.
    JAMA Oncol. 2022 Dec 29. doi: 10.1001/jamaoncol.2022.6109.
    PubMed     Abstract available
    
    
    
35. PROVENCIO M, Ortega AL, Coves-Sarto J, Calvo V, et al
    Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer With High Tumor Mutation Burden: A Nonrandomized Controlled Trial.
    JAMA Oncol. 2022 Dec 15. doi: 10.1001/jamaoncol.2022.5959.
    PubMed     Abstract available
    
    
    
36. PETTY WJ, Paz-Ares L
    Emerging Strategies for the Treatment of Small Cell Lung Cancer: A Review.
    JAMA Oncol. 2022 Dec 15. doi: 10.1001/jamaoncol.2022.5631.
    PubMed     Abstract available
    
    
    
37. KREBS MG, Malapelle U, Andre F, Paz-Ares L, et al
    Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients With Cancer: A Narrative Review.
    JAMA Oncol. 2022;8:1830-1839.
    PubMed     Abstract available
    
    
    November 2022
38. DESAI AP, Adashek JJ, Reuss JE, West HJ, et al
    Perioperative Immune Checkpoint Inhibition in Early-Stage Non-Small Cell Lung Cancer: A Review.
    JAMA Oncol. 2022 Nov 17. pii: 2798846. doi: 10.1001/jamaoncol.2022.5389.
    PubMed     Abstract available
    
    
    
39. KATZ MS, Russo GA
    Defining a Therapeutic Ratio for Stereotactic Ablative Radiation Therapy in Oligometastatic Disease-Another Piece of the Puzzle.
    JAMA Oncol. 2022;8:1650-1651.
    PubMed    
    
    
    
40. OLSON R, Jiang W, Liu M, Bergman A, et al
    Treatment With Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients With Cancer: Primary Toxic Effect Results of the Nonrandomized Phase 2 SABR-5 Clinical Trial.
    JAMA Oncol. 2022;8:1644-1650.
    PubMed     Abstract available
    
    
    
41. STROHBEHN GW, Holleman R, Burns J, Klamerus ML, et al
    Adoption of Extended-Interval Dosing of Single-Agent Pembrolizumab and Comparative Effectiveness vs Standard Dosing in Time-to-Treatment Discontinuation.
    JAMA Oncol. 2022;8:1663-1667.
    PubMed     Abstract available
    
    
    October 2022
42. CANOVA S, Arcangeli S, Cortinovis DL
    A Cast of Shadow on Postoperative Radiotherapy for pIIIA-N2 Non-Small Cell Lung Cancer?
    JAMA Oncol. 2022 Oct 13. pii: 2797485. doi: 10.1001/jamaoncol.2022.4442.
    PubMed    
    
    
    
43. MORIZANE C, Machida N, Honma Y, Okusaka T, et al
    Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial.
    JAMA Oncol. 2022;8:1447-1455.
    PubMed     Abstract available
    
    
    September 2022
44. KIM KH, Oh J, Yang G, Lee J, et al
    Association of Sinoatrial Node Radiation Dose With Atrial Fibrillation and Mortality in Patients With Lung Cancer.
    JAMA Oncol. 2022 Sep 22. pii: 2796765. doi: 10.1001/jamaoncol.2022.4202.
    PubMed     Abstract available
    
    
    
45. VOLK RJ, Stacey D
    Ensuring High-Quality Shared Decision-making for Lung Cancer Screening.
    JAMA Oncol. 2022 Sep 8. pii: 2796098. doi: 10.1001/jamaoncol.2022.3766.
    PubMed    
    
    
    
46. GERBER DE, Singh H, Larkins E, Ferris A, et al
    A New Approach to Simplifying and Harmonizing Cancer Clinical Trials-Standardizing Eligibility Criteria.
    JAMA Oncol. 2022;8:1333-1339.
    PubMed     Abstract available
    
    
    August 2022
47. RICCIUTI B, Wang X, Alessi JV, Rizvi H, et al
    Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels.
    JAMA Oncol. 2022;8:1160-1168.
    PubMed     Abstract available
    
    
    July 2022
48. DESAI A, Velazquez AI, West HJ
    Perioperative Therapy in Early-Stage Lung Cancer.
    JAMA Oncol. 2022 Jul 28. pii: 2794804. doi: 10.1001/jamaoncol.2022.1940.
    PubMed    
    
    
    
49. FASELIS C, Nations JA, Morgan CJ, Antevil J, et al
    Assessment of Lung Cancer Risk Among Smokers for Whom Annual Screening Is Not Recommended.
    JAMA Oncol. 2022 Jul 28. pii: 2794805. doi: 10.1001/jamaoncol.2022.2952.
    PubMed     Abstract available
    
    
    
50. XU J, Liu Z, Bai H, Dong G, et al
    Evaluation of Clinical Outcomes of Icotinib in Patients With Clinically Diagnosed Advanced Lung Cancer With EGFR-Sensitizing Variants Assessed by Circulating Tumor DNA Testing: A Phase 2 Nonrandomized Clinical Trial.
    JAMA Oncol. 2022 Jul 21. pii: 2794634. doi: 10.1001/jamaoncol.2022.2719.
    PubMed     Abstract available
    
    
    April 2022
51. LOUIE AV, Granton PV, Fairchild A, Bezjak A, et al
    Palliative Radiation for Advanced Central Lung Tumors With Intentional Avoidance of the Esophagus (PROACTIVE): A Phase 3 Randomized Clinical Trial.
    JAMA Oncol. 2022;8:1-7.
    PubMed     Abstract available
    
    
    March 2022
52. KEHL KL, Zahrieh D, Yang P, Hillman SL, et al
    Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216).
    JAMA Oncol. 2022 Mar 17. pii: 2790373. doi: 10.1001/jamaoncol.2022.0039.
    PubMed     Abstract available
    
    
    
53. ARRIETA O, Zatarain-Barron ZL, Turcott JG, Barron F, et al
    Association of BMI With Benefit of Metformin Plus Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients With Advanced Lung Adenocarcinoma: A Secondary Analysis of a Phase 2 Randomized Clinical Trial.
    JAMA Oncol. 2022;8:477-479.
    PubMed    
    
    
    February 2022
54. ROBBINS HA, Landy R, Ahluwalia JS
    Achieving Equity in Lung Cancer Screening for Black Individuals Requires Innovation to Move Beyond "Equal" Guidelines.
    JAMA Oncol. 2022 Feb 24. pii: 2789385. doi: 10.1001/jamaoncol.2021.7252.
    PubMed    
    
    
    
55. ZHAO B, Ma W
    Nivolumab Plus Ipilimumab for Previously Treated Stage IV Squamous Cell Lung Cancer.
    JAMA Oncol. 2022 Feb 10. pii: 2789076. doi: 10.1001/jamaoncol.2021.7784.
    PubMed    
    
    
    
56. GIL-SIERRA MD, Del Pilar Briceno-Casado M, Sanchez-Hidalgo M
    Nivolumab Plus Ipilimumab for Previously Treated Stage IV Squamous Cell Lung Cancer.
    JAMA Oncol. 2022 Feb 10. pii: 2789075. doi: 10.1001/jamaoncol.2021.7787.
    PubMed    
    
    
    
57. GETTINGER S, Redman MW, Herbst RS
    Nivolumab Plus Ipilimumab for Previously Treated Stage IV Squamous Cell Lung Cancer-Reply.
    JAMA Oncol. 2022 Feb 10. pii: 2789074. doi: 10.1001/jamaoncol.2021.7790.
    PubMed    
    
    
    
58. HE MM, Lo CH, Wang K, Polychronidis G, et al
    Immune-Mediated Diseases Associated With Cancer Risks.
    JAMA Oncol. 2022;8:209-219.
    PubMed     Abstract available
    
    
    
59. BROWN S, Lavery JA, Shen R, Martin AS, et al
    Implications of Selection Bias Due to Delayed Study Entry in Clinical Genomic Studies.
    JAMA Oncol. 2022;8:287-291.
    PubMed     Abstract available
    
    
    January 2022
60. ZHANG-VELTEN E, Iyengar P, Timmerman RD
    Hypofractionated Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer-Does Size Matter?-Reply.
    JAMA Oncol. 2022 Jan 13. pii: 2788056. doi: 10.1001/jamaoncol.2021.7160.
    PubMed    
    
    
    
61. OHRI N, Werner-Wasik M
    Hypofractionated Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer-Does Size Matter?
    JAMA Oncol. 2022 Jan 13. pii: 2788057. doi: 10.1001/jamaoncol.2021.7157.
    PubMed    
    
    
    
62. PU CY, Lusk CM, Neslund-Dudas C, Gadgeel S, et al
    Comparison Between the 2021 USPSTF Lung Cancer Screening Criteria and Other Lung Cancer Screening Criteria for Racial Disparity in Eligibility.
    JAMA Oncol. 2022 Jan 13. pii: 2788055. doi: 10.1001/jamaoncol.2021.6720.
    PubMed     Abstract available
    
    
    
63. NITZ JA, Erkmen CP
    New 2021 USPSTF Lung Cancer Screening Criteria-An Opportunity to Mitigate Racial Disparity.
    JAMA Oncol. 2022 Jan 13. pii: 2788059. doi: 10.1001/jamaoncol.2021.6708.
    PubMed    
    
    
    December 2021
64. NEBHAN CA, Cortellini A, Ma W, Ganta T, et al
    Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study.
    JAMA Oncol. 2021;7:1856-1861.
    PubMed     Abstract available
    
    
    November 2021
65. POTTER AL, Yang CJ, Woolpert KM, Puttaraju T, et al
    Evaluating Eligibility of US Black Women Under USPSTF Lung Cancer Screening Guidelines.
    JAMA Oncol. 2021 Nov 24. pii: 2786539. doi: 10.1001/jamaoncol.2021.5790.
    PubMed    
    
    
    
66. KAPOOR A, Prabhash K
    Analysis of Outcomes With Addition of Immunotherapy to Chemoradiation Therapy for Non-Small Cell Lung Cancer.
    JAMA Oncol. 2021 Nov 4. pii: 2785696. doi: 10.1001/jamaoncol.2021.5608.
    PubMed    
    
    
    
67. TIAN L, Huang B, Wei LJ
    Analysis of Outcomes With Addition of Immunotherapy to Chemoradiation Therapy for Non-Small Cell Lung Cancer.
    JAMA Oncol. 2021 Nov 4. pii: 2785697. doi: 10.1001/jamaoncol.2021.5605.
    PubMed    
    
    
    
68. JABBOUR SK, Keller SM, Reck M
    Analysis of Outcomes With Addition of Immunotherapy to Chemoradiation Therapy for Non-Small Cell Lung Cancer-Reply.
    JAMA Oncol. 2021 Nov 4. pii: 2785695. doi: 10.1001/jamaoncol.2021.5611.
    PubMed    
    
    
    October 2021
69. SINGH H, Beaver JA, Pazdur R
    Immunotherapy for Patients With Small-Cell Lung Cancer-2 Gains, 2 Losses.
    JAMA Oncol. 2021 Oct 28. pii: 2785674. doi: 10.1001/jamaoncol.2021.4956.
    PubMed    
    
    
    
70. MULSHINE JL, Pyenson B
    The Long, Slow Road to Lung Cancer Cure.
    JAMA Oncol. 2021 Oct 21. pii: 2784991. doi: 10.1001/jamaoncol.2021.4711.
    PubMed    
    
    
    
71. GANTI AK, Klein AB, Cotarla I, Seal B, et al
    Update of Incidence, Prevalence, Survival, and Initial Treatment in Patients With Non-Small Cell Lung Cancer in the US.
    JAMA Oncol. 2021 Oct 21. pii: 2784988. doi: 10.1001/jamaoncol.2021.4932.
    PubMed     Abstract available
    
    
    
72. TOUMAZIS I, de Nijs K, Cao P, Bastani M, et al
    Cost-effectiveness Evaluation of the 2021 US Preventive Services Task Force Recommendation for Lung Cancer Screening.
    JAMA Oncol. 2021 Oct 21. pii: 2784987. doi: 10.1001/jamaoncol.2021.4942.
    PubMed     Abstract available
    
    
    
73. ZHOU C, Ramalingam SS, Kim TM, Kim SW, et al
    Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial.
    JAMA Oncol. 2021 Oct 14:e214761. doi: 10.1001/jamaoncol.2021.4761.
    PubMed     Abstract available
    
    
    
74. AMINI A
    Managing Pulmonary Oligometastatic Disease With Stereotactic Body Radiation Therapy-Moving the Field Forward 1 Organ at a Time.
    JAMA Oncol. 2021;7:1485-1486.
    PubMed    
    
    
    
75. HUANG S, Gao Z, Qiao G
    Immunochemotherapy as First-line Treatment for Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancers.
    JAMA Oncol. 2021;7:1580.
    PubMed    
    
    
    
76. WANG J, Leaw SJ, Lu S
    Immunochemotherapy as First-line Treatment for Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancers-Reply.
    JAMA Oncol. 2021;7:1580-1581.
    PubMed    
    
    
    September 2021
77. DAGOGO-JACK I
    Inserting Ensartinib Into the Starting Lineup for ALK-Rearranged Lung Cancer-A Likely Limited Role on a Deep Bench.
    JAMA Oncol. 2021 Sep 2. pii: 2783495. doi: 10.1001/jamaoncol.2021.3369.
    PubMed    
    
    
    
78. HORN L, Wang Z, Wu G, Poddubskaya E, et al
    Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial.
    JAMA Oncol. 2021 Sep 2. pii: 2783490. doi: 10.1001/jamaoncol.2021.3523.
    PubMed     Abstract available
    
    
    August 2021
79. KHANDEKAR MJ, Keane FK
    Radiation Dose and Fractionation in Locally Advanced Lung Cancer: A Simple Question With a Complicated Answer.
    JAMA Oncol. 2021 Aug 12. pii: 2783009. doi: 10.1001/jamaoncol.2021.3180.
    PubMed    
    
    
    
80. IYENGAR P, Zhang-Velten E, Court L, Westover K, et al
    Accelerated Hypofractionated Image-Guided vs Conventional Radiotherapy for Patients With Stage II/III Non-Small Cell Lung Cancer and Poor Performance Status: A Randomized Clinical Trial.
    JAMA Oncol. 2021 Aug 12. pii: 2783004. doi: 10.1001/jamaoncol.2021.3186.
    PubMed     Abstract available
    
    
    July 2021
81. EZE C, Belka C, Manapov F
    Forging a Path for Metformin Use in Inoperable Locally Advanced Non-Small Cell Lung Cancer.
    JAMA Oncol. 2021 Jul 29. pii: 2782115. doi: 10.1001/jamaoncol.2021.2316.
    PubMed    
    
    
    
82. TSAKIRIDIS T, Pond GR, Wright J, Ellis PM, et al
    Metformin in Combination With Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer: The OCOG-ALMERA Randomized Clinical Trial.
    JAMA Oncol. 2021 Jul 29. pii: 2782110. doi: 10.1001/jamaoncol.2021.2328.
    PubMed     Abstract available
    
    
    
83. SKINNER H, Hu C, Tsakiridis T, Santana-Davila R, et al
    Addition of Metformin to Concurrent Chemoradiation in Patients With Locally Advanced Non-Small Cell Lung Cancer: The NRG-LU001 Phase 2 Randomized Clinical Trial.
    JAMA Oncol. 2021 Jul 29. pii: 2782111. doi: 10.1001/jamaoncol.2021.2318.
    PubMed     Abstract available
    
    
    
84. GETTINGER SN, Redman MW, Bazhenova L, Hirsch FR, et al
    Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial.
    JAMA Oncol. 2021 Jul 15. pii: 2781889. doi: 10.1001/jamaoncol.2021.2209.
    PubMed     Abstract available
    
    
    
85. HUANG H, Feng YL, Liu JH
    Sequential Chemoradiotherapy vs Concurrent Chemoradiotherapy or Radiotherapy Alone in Adjuvant Treatment for Patients With Cervical Cancer-Reply.
    JAMA Oncol. 2021 Jul 15. pii: 2781892. doi: 10.1001/jamaoncol.2021.2113.
    PubMed    
    
    
    
86. SARI SY, Kahvecioglu A, Yildiz F
    Sequential Chemoradiotherapy vs Concurrent Chemoradiotherapy or Radiotherapy Alone in Adjuvant Treatment for Patients With Cervical Cancer.
    JAMA Oncol. 2021 Jul 15. pii: 2781893. doi: 10.1001/jamaoncol.2021.2110.
    PubMed    
    
    
    
87. BARTELS F, Wandrey MM, Aigner A, Stronisch T, et al
    Association Between Neuronal Autoantibodies and Cognitive Impairment in Patients With Lung Cancer.
    JAMA Oncol. 2021 Jul 1. pii: 2781389. doi: 10.1001/jamaoncol.2021.2049.
    PubMed     Abstract available
    
    
    
88. JACOBSON JO
    Accompanying Patients in the Time of COVID-19.
    JAMA Oncol. 2021;7:971-972.
    PubMed    
    
    
    June 2021
89. HUI Z, Men Y, Hu C, Kang J, et al
    Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non-Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy: The Phase 3 PORT-C Randomized Clinical Trial.
    JAMA Oncol. 2021 Jun 24. pii: 2781087. doi: 10.1001/jamaoncol.2021.1910.
    PubMed     Abstract available
    
    
    
90. JABBOUR SK, Lee KH, Frost N, Breder V, et al
    Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial.
    JAMA Oncol. 2021 Jun 4. pii: 2780855. doi: 10.1001/jamaoncol.2021.2301.
    PubMed     Abstract available
    
    
    
91. TAKSLER GB, Peterse EFP, Willems I, Ten Haaf K, et al
    Modeling Strategies to Optimize Cancer Screening in USPSTF Guideline-Noncompliant Women.
    JAMA Oncol. 2021;7:885-894.
    PubMed     Abstract available
    
    
    
92. CHMURA S, Winter KA, Robinson C, Pisansky TM, et al
    Evaluation of Safety of Stereotactic Body Radiotherapy for the Treatment of Patients With Multiple Metastases: Findings From the NRG-BR001 Phase 1 Trial.
    JAMA Oncol. 2021;7:845-852.
    PubMed     Abstract available
    
    
    May 2021
93. CORBETT K, Sharma A, Pond GR, Brastianos PK, et al
    Central Nervous System-Specific Outcomes of Phase 3 Randomized Clinical Trials in Patients With Advanced Breast Cancer, Lung Cancer, and Melanoma.
    JAMA Oncol. 2021 May 20. pii: 2780060. doi: 10.1001/jamaoncol.2021.1359.
    PubMed    
    
    
    
94. DEL PAGGIO JC, Berry JS, Hopman WM, Eisenhauer EA, et al
    Evolution of the Randomized Clinical Trial in the Era of Precision Oncology.
    JAMA Oncol. 2021;7:728-734.
    PubMed     Abstract available
    
    
    
95. HOROWITZ DP, Goodman K, Kachnic LA
    Ablative Radiotherapy for Patients With Inoperable Pancreas Cancer-Ready for Prime Time?
    JAMA Oncol. 2021;7:687-688.
    PubMed    
    
    
    
96. STELWAGEN J, de Vries EGE, Walenkamp AME
    Current Treatment Strategies and Future Directions for Extrapulmonary Neuroendocrine Carcinomas: A Review.
    JAMA Oncol. 2021;7:759-770.
    PubMed     Abstract available
    
    
    April 2021
97. SUN L, Tan M, Cohen RB, Langer CJ, et al
    Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor-Based Therapy in Patients With Advanced Non-Small-Cell Lung Cancer.
    JAMA Oncol. 2021 Apr 15. pii: 2778198. doi: 10.1001/jamaoncol.2021.0546.
    PubMed    
    
    
    
98. KAMRAN SC, Yeap BY, Ulysse CA, Cronin C, et al
    Assessment of a Contralateral Esophagus-Sparing Technique in Locally Advanced Lung Cancer Treated With High-Dose Chemoradiation: A Phase 1 Nonrandomized Clinical Trial.
    JAMA Oncol. 2021 Apr 8. pii: 2778095. doi: 10.1001/jamaoncol.2021.0281.
    PubMed     Abstract available
    
    
    
99. SHITARA K, Tabernero J
    Quantifying the Long-term Survival Benefit of Pembrolizumab for Patients With Advanced Gastric Cancer-Reply.
    JAMA Oncol. 2021;7:633.
    PubMed    
    
    
    
100. MCCAW ZR, Ludmir EB, Wei LJ
     Quantifying the Long-term Survival Benefit of Pembrolizumab for Patients With Advanced Gastric Cancer.
     JAMA Oncol. 2021;7:632-633.
     PubMed    
     
     
     January 2021
101. CHU CY, Er HP, Lin CC
     Progressive Dry Cough in a Patient With ROS1-Rearranged Lung Adenocarcinoma Undergoing Crizotinib Therapy.
     JAMA Oncol. 2021;7:124-125.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: